FDA Alerts Providers to Safety Risks Associated with Cesium Chloride

The Food and Drug Administration today alerted health care providers to safety risks associated with cesium chloride, a mineral salt sometimes taken by cancer patients who seek alternative treatments. Reported adverse events included QT prolongation (a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm), low potassium, seizures, potentially lethal arrhythmias, fainting, cardiac arrest and death. FDA also said it intends to move cesium chloride to the category of substances that present significant safety risks in compounding.
Related News Articles
Perspective
The 2025 AHA Leadership Summit wrapped up on July 22, and as always, it was energizing and inspiring to connect with so many talented and dedicated people…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
Carolyn Bogard, DNP, R.N., director of care coordination and palliative care at El Camino Health, talks about her system’s use of data to harness the passion…
Headline
The Food and Drug Administration has identified a Class I recall of certain lots of Medline Industries Craniotomy Kits containing recalled Codman…
Headline
Hartford HealthCare in Hartford, Conn., will receive the 2025 AHA Quest for Quality Prize as a result of their sweeping transformation over the past decade —…
Headline
A Q&A in the July edition of AHA Trustee Insights features leaders from Winchester Hospital in Massachusetts discussing the importance of board members…